American Journal of Cardiology
Volume 103, Issue 11 , Pages 1568-1571 , 1 June 2009

Effect on Serum Lipid Levels of Switching Dose of Ezetimibe from 10 to 5 mg

  • Lawrence Baruch, MD

      Affiliations

    • James J. Peters Veterans Affairs Medical Center, Bronx, New York
    • Mt. Sinai School of Medicine, New York, New York
    • Corresponding Author InformationCorresponding author: Tel: 718-584-9000, ext. 6771; fax: 718-741-4295
    • ,
  • Sanjay Agarwal, MD

      Affiliations

    • James J. Peters Veterans Affairs Medical Center, Bronx, New York
    • Mt. Sinai School of Medicine, New York, New York
    • ,
  • Bhanu Gupta, MD

      Affiliations

    • James J. Peters Veterans Affairs Medical Center, Bronx, New York
    • Mt. Sinai School of Medicine, New York, New York
    • ,
  • Ann Haynos, BA

      Affiliations

    • James J. Peters Veterans Affairs Medical Center, Bronx, New York
    • ,
  • Calvin Eng, MD

      Affiliations

    • James J. Peters Veterans Affairs Medical Center, Bronx, New York
    • Mt. Sinai School of Medicine, New York, New York

Received 21 November 2008 ,Revised 31 January 2009 ,Accepted 31 January 2009.

References 

  1. Dujovne CA, Ettinger MP, McNeer JF, Lipka LJ, LeBeaut AP, Suresh R, et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol. 2002;90:1092–1097
  2. Knopp RH, Gitter H, Truitt T, Bays H, Manion CV, Lipka LJ, et al Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J. 2003;24:729–741
  3. Stein E. Results of phase I/II clinical trials with ezetimibe, a novel selective cholesterol absorption inhibitor. Eur Heart J Suppl. 2001;3(suppl):E11–E16
  4. Bays HE, Moore PB, Drehobl MA, Rosenblatt S, Toth PD, Dujovne CA, et al Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther. 2001;23:1209–1230
  5. Dujovne CA, Bays H, Davidson MH, Knopp R, Hunninghake DB, Stein EA, et al. Reduction of LDL cholesterol in patients with primary hypercholesterolemia by SCH 48461: results of a multicenter dose-ranging study. J Clin Pharmacol. 2001;41:70–78
  6. Kosoglou T, Statkevich P, Meyer I, Cutler DL, Musiol B, Yang B, et al. Effects of ezetimibe on the pharmacodynamics and pharmacokinetics of lovastatin. Curr Med Res Opin. 2004;20:955–965
  7. Baruch L, Gupta B, Lieberman-Blum SS, Agarwal S, Eng C. Ezetimibe 5 and 10 mg for lowering LDL-C: potential billion-dollar savings with improved tolerability. Am J Manag Care. 2008;14:637–641
  8. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486–2497
  9. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–239
  10. Venero CV, Seip RL, Thompson PD. Effectiveness of thrice weekly ezetimibe. Am J Cardiol. 2008;102:1205–1206

PII: S0002-9149(09)00537-2

doi: 10.1016/j.amjcard.2009.01.365

American Journal of Cardiology
Volume 103, Issue 11 , Pages 1568-1571 , 1 June 2009

Article Tools

* Image Usage & Resolution